In particular, they have shown a reduction of major adverse cardiovascular events (MACE) in diabetic patients at high cardiovascular risk [23,24,25,26,27,28,29,30]
*Contraindications weight loss injections include a personal or family history of medullary thyroid cancer, allergy to GLP-1 and weight loss injections, Type 1 Diabetes or history of Diabetic Ketoacidosis, personal or family history of Multiple Endocrine Neoplasia, personal history of Pancreatitis, renal impairment or kidney disease, gallbladder disease, or concurrent use of anti-diabetic medications or insulin
Individuals seeking targeted probiotic strains associated with metabolic pathways
Collagen protects your skin
These results provide compelling evidence that semaglutide reduces ASCVD risk also in patients with obesity and established ASCVD but not T2D, laying groundwork for novel therapeutic strategies for the treatment of obesity in people with high risk for CV events
Tuttle, M.C